# WELIREG® (belzutifan) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/belzutifan

> The FDA approved WELIREG® (belzutifan), sponsored by Merck & Co., Inc. (MRK), on August 13, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | WELIREG® (belzutifan) |
| Codes | MK-6482, PT2977 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Metastatic Breast Cancer](https://sec-api.dev/indications/metastatic-breast-cancer), [Carcinoma, Renal Cell](https://sec-api.dev/indications/carcinoma-renal-cell) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### August 13, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215383 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210813, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22

### December 14, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215383 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20231214, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22

### April 15, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215383 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20250415, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22
- openFDA Drugs@FDA: "NDA215383 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250415, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22

### May 14, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215383 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20250514, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22

### February 2, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Carcinoma, Renal Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04586231 (A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-02 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04586231

### June 12, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215383 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22

### June 19, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact. Stage: 3.
- First seen 2026-02-24, last confirmed 2026-05-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-052081): "Patients With Earlier-Stage RCC; Results From Phase 3 LITESPARK-022 Trial; FDA Set PDUFA Date of June 19, 2026 for WELIREG in combination with KEYTRUDA or KEYTRUDA QLEX" https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm
- SEC Form 10-Q (accession 0001628280-26-029802): "The FDA set a PDUFA date of June 19, 2026." https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm
- SEC Form 10-K (accession 0000310158-26-000063): "The FDA set a PDUFA date of June 19, 2026." https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-052081): "§ FDA set PDUFA date of June 19, 2026." https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm
- openFDA Drugs@FDA: "NDA215383 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22

### September 24, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215383 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20260924, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Carcinoma, Renal Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05239728 (A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05239728

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Carcinoma, Renal Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05239728 (A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05239728

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Metastatic Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06428396 (Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06428396

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Metastatic Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06428396 (Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06428396

## Same indication

- [Lasofoxifene in combination with abemaciclib](https://sec-api.dev/pdufa/lasofoxifene-in-combination-with-abemaciclib) (LONA)
- [Sacituzumab govitecan-hziy](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) (GILD)

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10), [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/belzutifan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "WELIREG® (belzutifan) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/belzutifan

```bibtex
@misc{secapidev_pdufa_belzutifan_20261116,
  title        = {WELIREG® (belzutifan) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/belzutifan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_belzutifan_20261116","title":"WELIREG® (belzutifan) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/belzutifan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
